Manzione N C, Goldfarb J P, LeJemtel T H, Maskin C S, Sternlieb I
Am J Med Sci. 1986 Feb;291(2):88-92. doi: 10.1097/00000441-198602000-00003.
The aminopyrine breath test (APBT) was used to study patients with chronic congestive heart failure before and after treatment with two chemically similar inotropic agents, amrinone (AR) and milrinone (MR), to determine their effects on hepatic microsomal function. Liver chemistries and cardiac indices were measured and correlated with the 2-hour APBT score in 11 patients with chronic congestive heart failure (5 treated with AR, 6 with MR) and five healthy control subjects. Despite normal or near-normal liver chemistries, patients with chronic congestive heart failure demonstrated overall depressed hepatic microsomal oxidative function. Patients with severe congestive heart failure had a lower mean pretreatment APBT score (AR = 3.05 +/- 1.02, MR = 5.38 +/- 3.09) when compared with healthy controls (10.02 +/- 1.02). However, the APBT score for each individual could not be predicted from the cardiac index. Although the mean cardiac index increased significantly in both the AR and the MR treated patients by 26.14% +/- 15.28 (p less than 0.01) and 40.0% +/- 42.27 (p less than 0.025), respectively, compared with pretreatment values, the mean APBT score fell by 62.02% +/- 22.5 (p less than 0.005) in the former and increased by 38.35% +/- 25.69 (p less than 0.01) in the patients receiving MR. This discordance between the effects of AR and MR suggests possible differences in the effects of the two drugs on hepatic microsomal function.
氨基比林呼吸试验(APBT)被用于研究慢性充血性心力衰竭患者在接受两种化学结构相似的强心剂氨力农(AR)和米力农(MR)治疗前后的情况,以确定它们对肝微粒体功能的影响。对11例慢性充血性心力衰竭患者(5例接受AR治疗,6例接受MR治疗)和5名健康对照者测量了肝功能和心脏指数,并将其与2小时APBT评分进行关联。尽管肝功能正常或接近正常,但慢性充血性心力衰竭患者的肝微粒体氧化功能总体上受到抑制。与健康对照者(10.02±1.02)相比,重度充血性心力衰竭患者的平均治疗前APBT评分较低(AR = 3.05±1.02,MR = 5.38±3.09)。然而,无法根据心脏指数预测每个个体的APBT评分。尽管与治疗前值相比,接受AR和MR治疗的患者的平均心脏指数分别显著增加了26.14%±15.28(p<0.01)和40.0%±42.27(p<0.025),但接受AR治疗的患者的平均APBT评分下降了62.02%±22.5(p<0.005),而接受MR治疗的患者的平均APBT评分增加了38.35%±25.69(p<0.01)。AR和MR的作用之间的这种不一致表明这两种药物对肝微粒体功能的影响可能存在差异。